LINFOMAS Y TRASPLANTES
Universitat de Barcelona
Barcelona, EspañaPublications in collaboration with researchers from Universitat de Barcelona (36)
2024
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
-
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
HemaSphere, Vol. 8, Núm. 5
2023
-
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets
American Journal of Hematology
-
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Blood Advances
-
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study
Transplantation and Cellular Therapy, Vol. 29, Núm. 12, pp. 747.e1-747.e10
-
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211
-
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Blood Cancer Journal, Vol. 13, Núm. 1
-
Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4
-
Unraveling the genetics of transformed splenic marginal zone lymphoma
Blood Advances, Vol. 7, Núm. 14, pp. 3695-3709
2022
-
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067
-
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Frontiers in Immunology, Vol. 13
-
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation
British Journal of Haematology, Vol. 196, Núm. 1, pp. 146-155
-
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
Nature Medicine, Vol. 28, Núm. 8, pp. 1662-1671
-
Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
Histopathology, Vol. 81, Núm. 6, pp. 826-840
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT
British Journal of Haematology, Vol. 196, Núm. 4, pp. 1018-1030
-
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
Leukemia and Lymphoma, Vol. 63, Núm. 9, pp. 2063-2073
-
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma
British Journal of Haematology, Vol. 196, Núm. 3, pp. 589-598
-
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Journal of hematology & oncology, Vol. 15, Núm. 1, pp. 54